Two genetically-modified broadly-neutralizing antibodies have been demonstrated to elicit long-term protection against an HIV-like virus in rhesus macaques, with a Phase I clinical trial now underway.
New research has suggested that a protein involved in Alzheimer’s disease may also be implicated in HIV-associated neurological disorders, suggesting Alzheimer’s therapies may benefit a subset of HIV patients.
Mylan N.V have announced they’ll be launching their third HIV combination in the US, following FDA approval of their once-daily treatment Symfi™.
TB and HIV are two intertwined infective challenges for global health and therefore they need to be addressed with an integrated approach.
Partnership announcements and promising trial data reported at the 2018 Conference on Retroviruses and Opportunistic Infections, take a look at our round-up of the latest industry headlines.
For International Women’s Day, we spoke to Sharon Lewin about her typical day, who inspires her and her great deal of international travel!
In our latest infographic we provide a visual snapshot of the infections and immune processes that have been linked with the microbiome thus far, explaining some of the evidence
With the microbiome becoming a much talked about topic in recent years, we spoke to Sergio Serrano-Villar, author of Future Microbiology’s top-read article of 2017 entitled: ‘How can the gut microbiota affect immune recovery in HIV infected individuals?’.
Take a look at the top news stories of the week, including the FDA approval of HIV drug Biktarvy and the discovery of a genetic predisposition to congenital Zika syndrome.
A biothreat agent is defined as a biological weapon employed to deliberately cause disease, but how real are such threats, and what should our approach be towards them?
